Swetang J Shah, MD
Pediatric Medicine · Gilroy
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 1 carrier
- Offices
- 2
Offices
2 locations · Bay Area Community Health · 106 clinicians in this group
Looking this up.
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Shah’s office at (408) 729-9700 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A136884 · Current
Licensed to practise in California · since 2015 · expires 2028-09-30 · Maharashtra University of Health Sciences, Ndmvp Samaj'S Medical College.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$874,879 in 2024
Medicaid paid $874,879 for 11,833 billed services this clinician did in 2024, up to 310 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 2,656 | $739,740 |
| Other specified case management service not elsewhere classified | 683 | $60,441 |
| Short return visit (20+ min) | 2,931 | $27,630 |
| Return visit (30+ min) | 892 | $9,970 |
| Developmental screening | 461 | $7,719 |
| Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use | 199 | $5,601 |
| Long return visit (40+ min) | 224 | $4,011 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 125 | $3,461 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 126 | $3,366 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 198 | $2,590 |
| Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | 82 | $2,093 |
| Hepatitis B vaccine (HepB), CpG-adjuvanted, adult dosage, 2 dose or 4 dose schedule, for intramuscular use | 31 | $2,000 |
| 2024 | 11,833 | 40 | 310 | $874,879 |
| 2023 | 14,274 | 44 | 471 | $1,255,129 |
| 2022 | 11,172 | 34 | 317 | $383,598 |
| 2021 | 13,092 | 29 | 271 | $465,677 |
| 2020 | 13,532 | 25 | 302 | $481,927 |
| 2019 | 12,352 | 25 | 383 | $562,826 |
| 2018 | 9,837 | 19 | 423 | $635,902 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 3,877 | $1,031,225 |
| Other specified case management service not elsewhere classified | 1,084 | $169,280 |
| Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use | 151 | $9,444 |
| Short return visit (20+ min) | 3,416 | $8,448 |
| Developmental screening | 248 | $5,543 |
| Coordinated care fee, physician coordinated care oversight services | 128 | $5,121 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 162 | $3,588 |
| Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use | 207 | $3,085 |
| Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use | 25 | $2,961 |
| Return visit (30+ min) | 752 | $2,334 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 105 | $1,976 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 146 | $1,578 |
2022
| Clinic visit/encounter, all-inclusive | 2,549 | $379,159 |
| Initial hospital or birthing center care, per day, for evaluation and management of normal newborn infant | 115 | $2,031 |
| Short return visit (20+ min) | 2,087 | $864 |
| Hospital inpatient or observation discharge day management; 30 minutes or less on the date of the encounter | 30 | $569 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 552 | $438 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 166 | $117 |
| Short return visit | 1,160 | $98 |
| Screening performed and negative | 327 | $87 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 222 | $87 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 469 | $37 |
| Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | 406 | $27 |
| Screening test, pure tone, air only | 448 | $22 |
2021
| Clinic visit/encounter, all-inclusive | 3,252 | $465,168 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 584 | $190 |
| Initial hospital or birthing center care, per day, for evaluation and management of normal newborn infant | 100 | $102 |
| Short return visit (20+ min) | 1,845 | $79 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 534 | $71 |
| Screening performed and negative | 786 | $29 |
| Short return visit | 1,586 | $20 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Influenza | 28 | $18 |
| Measurement of lead | 142 | $0 |
| HEMOGLOBIN | 266 | $0 |
| Measurement of bilirubin | 70 | $0 |
| Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use | 110 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 3,472 | $481,848 |
| Short return visit | 1,719 | $79 |
| Measurement of lead | 181 | $0 |
| HEMOGLOBIN | 401 | $0 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Influenza | 103 | $0 |
| Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use | 161 | $0 |
| Haemophilus influenzae type b vaccine, PRP-OMP conjugate | 228 | $0 |
| Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | 393 | $0 |
| Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use | 248 | $0 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 453 | $0 |
| DIPHTH TETANUS TOX ACELL PERTUSSIS VACC<7 YR IM | 55 | $0 |
| Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use | 36 | $0 |
2019
| Clinic visit/encounter, all-inclusive | 4,161 | $562,192 |
| Hospital inpatient or observation discharge day management; 30 minutes or less on the date of the encounter | 75 | $505 |
| Initial hospital or birthing center care, per day, for evaluation and management of normal newborn infant | 37 | $103 |
| Short return visit (20+ min) | 1,870 | $26 |
| Measurement of lead | 231 | $0 |
| HEMOGLOBIN | 397 | $0 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Influenza | 83 | $0 |
| Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use | 231 | $0 |
| Haemophilus influenzae type b vaccine, PRP-OMP conjugate | 148 | $0 |
| Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | 286 | $0 |
| Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use | 177 | $0 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use | 25 | $0 |
2018
| Clinic visit/encounter, all-inclusive | 4,810 | $634,054 |
| Short return visit (20+ min) | 1,652 | $709 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 276 | $670 |
| Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | 277 | $86 |
| Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine (DTaP-HepB-IPV), for intramuscular use | 161 | $86 |
| Haemophilus influenzae type b vaccine, PRP-OMP conjugate | 137 | $77 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 396 | $74 |
| Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use | 104 | $68 |
| Screening test, pure tone, air only | 224 | $33 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 279 | $27 |
| Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use | 101 | $9 |
| HEMOGLOBIN | 320 | $8 |
Money from drug and device companies
$681 in 2025
| 2025 | 11 | 23 | None | $681 |
| 2024 | 10 | 25 | None | $551 |
| 2023 | 6 | 15 | None | $314 |
| 2019 | 1 | 1 | None | $106 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Phadia US | Immunocap | $145 | 3 payments
|
| Gilead Sciences | None | $142 | 6 payments
|
| Pfizer | Prevnar 20 | $91 | 3 payments
|
| Seqirus USA | Flucelvax | $65 | 2 payments
|
| GlaxoSmithKline | Shingrix | $51 | 2 payments
|
| Exact Sciences | Cologuard Collection Kit | $43 | 2 payments
|
See all 23 published payments
| Seqirus USA | Meals · 2025-11-11 | Flucelvax | $34 |
| GlaxoSmithKline | Meals · 2025-11-04 | Shingrix | $23 |
| Gilead Sciences | Meals · 2025-10-30 | None | $21 |
| Pfizer | Meals · 2025-10-13 | Abrysvo | $25 |
| Gilead Sciences | Meals · 2025-09-12 | None | $9 |
| Pfizer | Meals · 2025-08-18 | Prevnar 20 | $28 |
| GlaxoSmithKline | Meals · 2025-08-11 | Shingrix | $28 |
| Gilead Sciences | Meals · 2025-08-05 | None | $19 |
| Exact Sciences | Meals · 2025-07-29 | Cologuard Collection Kit | $21 |
| Gilead Sciences | Meals · 2025-07-22 | None | $34 |
| Gilead Sciences | Meals · 2025-07-22 | None | $24 |
| Regeneron Healthcare Solutions | Meals · 2025-07-07 | Dupixent | $21 |
| Pfizer | Meals · 2025-06-17 | Prevnar 20 | $38 |
| Dynavax Technologies | Meals · 2025-06-09 | Heplisav-B | $27 |
| Exact Sciences | Meals · 2025-05-19 | Cologuard Collection Kit | $22 |
| Gilead Sciences | Meals · 2025-04-29 | None | $35 |
| Novo Nordisk | Meals · 2025-04-21 | Ozempic | $28 |
| Phadia US | Meals · 2025-04-09 | Immunocap | $85 |
| Seqirus USA | Meals · 2025-03-25 | Fluad | $31 |
| ViiV Healthcare | Meals · 2025-03-14 | Apretude | $34 |
| Phadia US | Meals · 2025-02-28 | Immunocap | $49 |
| Sanofi Pasteur | Meals · 2025-02-26 | Vaxelis | $34 |
| Phadia US | Meals · 2025-01-17 | Immunocap | $11 |
See earlier years (2024, 2023, 2019)
2024: $551
| Pfizer | Abrysvo | $155 | 7 payments
|
| Gilead Sciences | None | $83 | 3 payments
|
| Hologic Sales and Service | Aptima | $70 | 3 payments
|
| Novo Nordisk | Ozempic | $58 | 3 payments
|
| Merck Sharp & Dohme | Gardasil | $53 | 2 payments
|
| Exact Sciences | Cologuard Collection Kit | $45 | 2 payments
|
| Phadia US | Immunocap | $30 | 2 payments
|
| Sanofi Pasteur | Beyfortus | $29 | 1 payment
|
| GlaxoSmithKline | Shingrix | $15 | 1 payment
|
| Dynavax Technologies | Heplisav-B | $14 | 1 payment
|
2023: $314
| GlaxoSmithKline | Arexvy | $160 | 9 payments
|
| Dynavax Technologies | Heplisav-B | $54 | 2 payments
|
| Hologic Sales and Service | Thinprep 2000 Processor | $29 | 1 payment
|
| Pfizer | Abrysvo | $26 | 1 payment
|
| Sanofi Pasteur | Beyfortus | $26 | 1 payment
|
| Dexcom | Dexcom G6 Transmitter | $19 | 1 payment
|
2019: $106
| Merck Sharp & Dohme | Gardasil | $106 | 1 payment
|
Professional record
- NPI
- 1053744375
- Licence
- CA 136884California A136884: Current · expires 2028-09-30
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Pediatrics (208000000X)
- Mailing address
- 305 E Center Ave, Visalia, CA, 93291
- NPI first listed
- 2013-08-11
- NPI last updated
- 2025-12-30
- NPI record certified
- 2025-12-30
This is when the NPI record was last certified, not a medical board exam.